Table 1 Patient, treatment, and toxicity data

Number of analyzed patients

9

Sex (number of male/female)

2/7

Treatment period

February 2023 to February 2024

Location of LMD^†

Brain only

Spine only

Brain and spine

Number of patients

4

0

4

Type of LMD

Linear

CSF-only

Linear and nodular

Number of patients

5

1

3

LMD diagnosis method

Imaging-only

CSF-only

Imaging and CSF

Number of patients

4

1

4

Tumor entity

NSCLC

SCLC

Breast

Esophageal

Gastric

Ovarian

Pancreatic

Number of patients

1

1

3

1

1

1

1

Presence of parenchymal brain metastases at time of pCSI

Yes

No

Number of patients

3

6

Extra-CNS disease status at pCSI

Active

Controlled

Number of patients

6

3

Concurrent chemotherapy

Yes

No

Number of patients

4

5

Concurrent targeted therapy

Yes

No

Number of patients

5

4

Concurrent immunotherapy

Yes

No

Number of patients

2

7

Median

Mean (SD)

IQR

Range

Age at start of pCSI (years)

58.6

58.3 (8.9)

51.8–67.2

45.4–70.9

Time from LMD diagnosis to pCSI start (days)

34

42.5 (18.7)

31–45

30–84

KPS before pCSI

80

76.6 (12.2)

70–80

50–90

Number of brain metastases at the time of pCSI

0

0.89 (1.9)

0–1

0–6

pCSI prescription dose (Gy RBE)

30

30.3 (1.0)

30–30

30–33

pCSI single fraction dose (Gy RBE)

3

3 (0)

3–3

3–3

Number of fractions

10

10.1 (0.3)

10–10

10–11

pCSI duration in days

13

14.1 (3.1)

13–14

11–21

KPS 30 days after pCSI

75

68.3 (16.0)

60–80

40–80

Clinical follow-up (months)

3.5

3.8 (3.4)

0.7–4.1

0.3–9.9

Radiographic follow-up (months)

3.5

5.2 (2.8)

3.4–7.7

3.4–9.9

Toxicity^‡

Absolute number observed (%)

Grade 1

Grade 2

Grade 3

Grade 4

Grade 5

Anemia

3 (50.0%)

2 (33.3%)

1 (16.6%)

0 (0%)

0 (0%)

Thrombocytopenia

2 (33.3%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

Leukopenia

2 (33.3%)

0 (0%)

1 (16.6%)

0 (0%)

0 (0%)

Fatigue

3 (50.0%)

2 (33.3%)

0 (0%)

0 (0%)

0 (0%)

Headache

2 (33.3%)

1 (16.6%)

1 (16.6%)

0 (0%)

0 (0%)

Nausea

0 (0%)

0 (0%)

2 (33.3%)

0 (0%)

0 (0%)

Weight Loss

2 (33.3%)

1 (16.6%)

1 (16.6%)

0 (0%)

0 (0%)

Generalized muscle weakness

2 (33.3%)

1 (16.6%)

1 (16.6%)

0 (0%)

0 (0%)

Alopecia

3 (50.0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

Anorexia

2 (33.3%)

0 (0%)

1 (16.6%)

0 (0%)

0 (0%)

Blurred vision

0 (0%)

2 (33.3%)

0 (0%)

0 (0%)

0 (0%)